BlackRock
INDP icon

BlackRock’s Indaptus Therapeutics INDP Stock Holding History

BlackRock’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 5064
2020
Q1 		$0 Hold
1
– – ﹤0.01% 5014
2019
Q4 		$1K Hold
1
– – ﹤0.01% 4931
2019
Q3 		$1K Hold
1
– – ﹤0.01% 4922
2019
Q2 		$8K Buy
+1
New +$12.6K ﹤0.01% 4784
2019
Q1 		– Sell
-4
Closed -$67K – 4983
2018
Q4 		$67K Buy
+4
New +$54.5K ﹤0.01% 4427

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock's INDP Position: Q2 2020 in Review

BlackRock sold out of Indaptus Therapeutics (INDP) in Q2 2020, closing a stake of 1 share.

BlackRock first reported a position in INDP in Q4 2018 and held it in 5 quarters. The position peaked at $67K in Q4 2018. 26 funds tracked by Wall St. Rank hold INDP as of Q2 2020.

  • BlackRock reported no remaining Indaptus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • BlackRock sold 1 Indaptus Therapeutics share in Q2 2020.
  • BlackRock first reported a position in Indaptus Therapeutics in Q4 2018 and held it in 5 quarters.
  • BlackRock's Indaptus Therapeutics position peaked at $67K in Q4 2018.
  • 26 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2020.

Based on BlackRock's 13F filing for Q2 2020, filed 14 Aug 2020.